{"id":20985,"date":"2017-03-13T17:20:31","date_gmt":"2017-03-13T16:20:31","guid":{"rendered":"http:\/\/cms.munich-startup.net\/?p=20985"},"modified":"2021-03-31T21:07:14","modified_gmt":"2021-03-31T19:07:14","slug":"breath-therapeutics-closes-series-a-financing-with-e435-million","status":"publish","type":"post","link":"https:\/\/cms.munich-startup.net\/en\/20985\/breath-therapeutics-closes-series-a-financing-with-e435-million\/","title":{"rendered":"Breath Therapeutics closes Series A financing with \u20ac43.5 million"},"content":{"rendered":"

A Series A financing round that is impressive: Overall <\/strong>43.5 million euros was <\/strong>Breath Therapeutics Holding BV. The spin-off of PARI Pharma GmbH from Starnberg develops inhaled aerosol therapeutics for rare lung diseases. <\/strong>The lead investors were Gimv and Sofinnova Partners, and Gilde Healthcare joined the consortium. PARI Pharma is supporting the program. With the funds raised, Breath Therapeutics plans to conduct Phase 3 trials in the US and Europe, as well as prepare for regulatory approval and commercialization.<\/strong><\/p>\n

The focus of Breath Therapeutics\u2019 development program is
\nDevelopment of a first-in-class therapy for the treatment of bronchiolitis obliterans syndrome (BOS). BOS is a rare, but usually fatal, lung disease that primarily affects transplant recipients. It is generally understood as chronic graft rejection and is the primary reason for the low five-year survival rates after lung transplantation.<\/p>\n

Based on work by PARI Pharma<\/a> and a lung transplant expert, Dr. Aldo Iacono, MD, from the University of Maryland (USA), Breath Therapeutics is developing a proprietary drug-device combination. The therapy consists of a formulation of liposomal cyclosporine A, which is delivered via an optimized eFlow\u00ae nebulizer. The nebulizer records patient adherence online. This approach is intended to enable safe, well-tolerated, and targeted delivery of the immunosuppressant directly into the lungs. Short treatment times also enable patient-friendly use.<\/p>\n

Excellent position to achieve groundbreaking progress<\/h3>\n

Breath Therapeutics is a spin-off of PARI Pharma, Starnberg, Germany. The founding and management team consists of experienced, internationally recognized experts in aerosol and immunosuppression therapy. Dr. Jens Stegemann<\/strong>, CEO of Breath Therapeutics, is optimistic about the future:<\/p>\n

"BOS is one of the deadliest lung diseases, and to date, no effective treatment is available. Our strategy is to deliver high concentrations of cyclosporine A directly into the small airways of the lungs. With the high-level consortium of investors and the world's best lung transplant centers on our side, we are in an excellent position to make groundbreaking progress in the fight against BOS."<\/p><\/blockquote>\n

Graziano Seghezzi<\/strong>, Partner at Sofinnova Partners, added:<\/p>\n

"We are very pleased to be investing in Breath Therapeutics. We were impressed by the highly talented and entrepreneurial team, as well as the potential of the near-market technology. Sofinnova Partners has extensive experience and expertise in successfully founding companies. We are happy to share our experience and resources with the team to support Breath Therapeutics on its growth path."<\/p><\/blockquote>\n<\/div>","protected":false},"excerpt":{"rendered":"

A remarkable Series A financing round: Breath Therapeutics Holding BV raised a total of \u20ac43.5 million. The spin-off of PARI Pharma GmbH, based in Starnberg, develops inhaled aerosol therapeutics for rare lung diseases. Lead investors were Gimv and Sofinnova Partners, and Gilde Healthcare joined the consortium. PARI Pharma is supporting the program. With...<\/p>","protected":false},"author":24,"featured_media":20989,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[5638,1],"tags":[2361,775],"acf":[],"yoast_head":"\nBreath Therapeutics schlie\u00dft Serie-A-Finanzierung mit 43,5 Millionen Euro ab - Munich Startup<\/title>\n<meta name=\"description\" content=\"Eine Serie-A-Finanzierungsrunde, die sich sehen lassen kann: Insgesamt 43,5 Millionen Euro konnte die Breath Therapeutics Holding BV einsammeln.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/cms.munich-startup.net\/en\/20985\/breath-therapeutics-closes-series-a-financing-with-e435-million\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Breath Therapeutics schlie\u00dft Serie-A-Finanzierung mit 43,5 Millionen Euro ab - Munich Startup\" \/>\n<meta property=\"og:description\" content=\"Eine Serie-A-Finanzierungsrunde, die sich sehen lassen kann: Insgesamt 43,5 Millionen Euro konnte die Breath Therapeutics Holding BV einsammeln.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/cms.munich-startup.net\/en\/20985\/breath-therapeutics-closes-series-a-financing-with-e435-million\/\" \/>\n<meta property=\"og:site_name\" content=\"Munich Startup\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/munichstartup\/\" \/>\n<meta property=\"article:published_time\" content=\"2017-03-13T16:20:31+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-03-31T19:07:14+00:00\" \/>\n<meta name=\"author\" content=\"Regina Bruckschl\u00f6gl\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:site\" content=\"@munich_startup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Regina Bruckschl\u00f6gl\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/\",\"url\":\"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/\",\"name\":\"Breath Therapeutics schlie\u00dft Serie-A-Finanzierung mit 43,5 Millionen Euro ab - Munich Startup\",\"isPartOf\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/03\/door-349807_1280.jpg\",\"datePublished\":\"2017-03-13T16:20:31+00:00\",\"dateModified\":\"2021-03-31T19:07:14+00:00\",\"author\":{\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f\"},\"description\":\"Eine Serie-A-Finanzierungsrunde, die sich sehen lassen kann: Insgesamt 43,5 Millionen Euro konnte die Breath Therapeutics Holding BV einsammeln.\",\"breadcrumb\":{\"@id\":\"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#primaryimage\",\"url\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/03\/door-349807_1280.jpg\",\"contentUrl\":\"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/03\/door-349807_1280.jpg\",\"width\":1280,\"height\":853},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/cms.munich-startup.net\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Breath Therapeutics schlie\u00dft Serie-A-Finanzierung mit 43,5 Millionen Euro ab\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/cms.munich-startup.net\/#website\",\"url\":\"https:\/\/cms.munich-startup.net\/\",\"name\":\"Munich Startup\",\"description\":\"Das offizielle Startup-Portal f\u00fcr M\u00fcnchen\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/cms.munich-startup.net\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f\",\"name\":\"Regina Bruckschl\u00f6gl\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g\",\"caption\":\"Regina Bruckschl\u00f6gl\"},\"description\":\"Nach eigenen Startup-Erfahrungen blickt sie als Redakteurin von Munich Startup nun aus einer anderen Perspektive auf die M\u00fcnchner Startup-Szene \u2013 und entdeckt dabei jeden Tag, wie vielf\u00e4ltig das M\u00fcnchner \u00d6kosystem ist. Startup Stories, die erz\u00e4hlt werden wollen!\",\"sameAs\":[\"https:\/\/cms.munich-startup.net\"],\"url\":\"https:\/\/cms.munich-startup.net\/en\/author\/regina\/\"}]}<\/script>\n<meta property=\"og:image\" content=\"https:\/\/cms.munich-startup.net\/en\/wp-content\/uploads\/2017\/03\/door-349807_1280.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1280\" \/>\n\t<meta property=\"og:image:height\" content=\"853\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Breath Therapeutics closes Series A financing with \u20ac43.5 million - Munich Startup","description":"A Series A financing round that is impressive: Breath Therapeutics Holding BV was able to raise a total of 43.5 million euros.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/cms.munich-startup.net\/en\/20985\/breath-therapeutics-closes-series-a-financing-with-e435-million\/","og_locale":"en_US","og_type":"article","og_title":"Breath Therapeutics schlie\u00dft Serie-A-Finanzierung mit 43,5 Millionen Euro ab - Munich Startup","og_description":"Eine Serie-A-Finanzierungsrunde, die sich sehen lassen kann: Insgesamt 43,5 Millionen Euro konnte die Breath Therapeutics Holding BV einsammeln.","og_url":"https:\/\/cms.munich-startup.net\/en\/20985\/breath-therapeutics-closes-series-a-financing-with-e435-million\/","og_site_name":"Munich Startup","article_publisher":"https:\/\/www.facebook.com\/munichstartup\/","article_published_time":"2017-03-13T16:20:31+00:00","article_modified_time":"2021-03-31T19:07:14+00:00","author":"Regina Bruckschl\u00f6gl","twitter_card":"summary_large_image","twitter_creator":"@munich_startup","twitter_site":"@munich_startup","twitter_misc":{"Written by":"Regina Bruckschl\u00f6gl","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/","url":"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/","name":"Breath Therapeutics closes Series A financing with \u20ac43.5 million - Munich Startup","isPartOf":{"@id":"https:\/\/cms.munich-startup.net\/#website"},"primaryImageOfPage":{"@id":"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#primaryimage"},"image":{"@id":"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#primaryimage"},"thumbnailUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/03\/door-349807_1280.jpg","datePublished":"2017-03-13T16:20:31+00:00","dateModified":"2021-03-31T19:07:14+00:00","author":{"@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f"},"description":"A Series A financing round that is impressive: Breath Therapeutics Holding BV was able to raise a total of 43.5 million euros.","breadcrumb":{"@id":"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#primaryimage","url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/03\/door-349807_1280.jpg","contentUrl":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/03\/door-349807_1280.jpg","width":1280,"height":853},{"@type":"BreadcrumbList","@id":"https:\/\/cms.munich-startup.net\/20985\/breath-therapeutics-schliesst-serie-a-finanzierung-mit-435-millionen-euro-ab\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/cms.munich-startup.net\/"},{"@type":"ListItem","position":2,"name":"Breath Therapeutics schlie\u00dft Serie-A-Finanzierung mit 43,5 Millionen Euro ab"}]},{"@type":"WebSite","@id":"https:\/\/cms.munich-startup.net\/#website","url":"https:\/\/cms.munich-startup.net\/","name":"Munich Startup","description":"The official startup portal for Munich","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/cms.munich-startup.net\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/4733256eff8ed883081bf4d616fa784f","name":"Regina Bruckschl\u00f6gl","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/cms.munich-startup.net\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b783cd1e1497db1e22684a06f3369381?s=96&d=blank&r=g","caption":"Regina Bruckschl\u00f6gl"},"description":"After her own startup experiences, she now looks at the Munich startup scene from a different perspective as an editor at Munich Startup \u2013 and discovers every day how diverse the Munich ecosystem is. Startup stories that beg to be told!","sameAs":["https:\/\/cms.munich-startup.net"],"url":"https:\/\/cms.munich-startup.net\/en\/author\/regina\/"}]},"og_image":[{"width":1280,"height":853,"url":"https:\/\/cms.munich-startup.net\/wp-content\/uploads\/2017\/03\/door-349807_1280.jpg","type":"image\/jpeg"}]},"_showyear":"","_inactive":"","_show_financing":"","_hide_on_map":"","_edit_lock":"1489419874:24","_edit_last":"3","_yoast_wpseo_focuskw":"Breath Therapeutics","_yoast_wpseo_metadesc":"Eine Serie-A-Finanzierungsrunde, die sich sehen lassen kann: Insgesamt 43,5 Millionen Euro konnte die Breath Therapeutics Holding BV einsammeln.","_yoast_wpseo_linkdex":"84","_thumbnail_id":"20989","wbounce_status":"default","_yoast_wpseo_primary_category":"5638","_yoast_wpseo_focuskw_text_input":"Breath Therapeutics","_yoast_wpseo_content_score":"30","ms_image_format":"","_ms_image_format":"","ms_dachzeile":"","_ms_dachzeile":"","ms_bump_post_date":"","_ms_bump_post_date":"","guest_author_name":"","_guest_author_name":"","guest_author_image":"","_guest_author_image":"","guest_author_description":"","_guest_author_description":"","ms_post_image_caption":"","_ms_post_image_caption":"","ms_post_image_credit":"","_ms_post_image_credit":"","suppress_startupbox":"","_suppress_startupbox":"","_yoast_wpseo_estimated-reading-time-minutes":"","_wp_old_date":"","_yoast_wpseo_title":"","_yoast_wpseo_wordproof_timestamp":"","footnotes":"","easy_language_simplification_original_id":"","easy_language_source_language":"","easy_language_simplification_language":"","easy_language_api":"","easy_language_prevent_automatic_mode":"","_wp_old_slug":"","_wp_trash_meta_status":"","_wp_trash_meta_time":"","easy_language_simplification_state_changed_from":"","easy_language_de_EL_changed":"","ms_competition_deadline":"","_ms_competition_deadline":"","_wpbitly":"","enclosure":"","_yoast_wpseo_meta-robots-noindex":"","_yoast_wpseo_meta-robots-nofollow":"","wbounce_template":"","wbounce_title":"","wbounce_text":"","wbounce_cta":"","wbounce_url":"","wbounce_override":"","_yoast_wpseo_opengraph-title":"","_yoast_wpseo_opengraph-description":"","_oembed_7131efca3705e16bd9da2c41df237660":"","_oembed_time_7131efca3705e16bd9da2c41df237660":"","_pprredirect_type":"","_pprredirect_url":"","_yoast_wpseo_opengraph-image":"","_yoast_wpseo_opengraph-image-id":"","_newsletterglue":"","easy_language_text_language":"","_wp_desired_post_slug":"","_relevanssi_noindex_reason":"","_links":{"self":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/20985"}],"collection":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/users\/24"}],"replies":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/comments?post=20985"}],"version-history":[{"count":1,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/20985\/revisions"}],"predecessor-version":[{"id":70872,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/posts\/20985\/revisions\/70872"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media\/20989"}],"wp:attachment":[{"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/media?parent=20985"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/categories?post=20985"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/cms.munich-startup.net\/en\/wp-json\/wp\/v2\/tags?post=20985"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}